Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is focused on the acquisition and development of new and innovative bio-medical product opportunities and businesses offering the potential of addressing significant unmet medical needs, and which also … Continue reading →

Cardium Therapeutics is a health sciences and regenerative medicine company whose focus is on the acquisition and development of innovative products with the potential to address significant unmet medical needs. These innovative products should have a definable pathway to commercialization … Continue reading →

Cardium Therapeutics today announced that Chairman & CEO Christopher J. Reinhard will be giving a presentation at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012, at 3:15 p.m. Eastern Time. The conference is being held … Continue reading →

Cardium Therapeutics, a San Diego based medical technology company, working with Michigan based Essen Bioscience, Inc., has come up with an important new bio-assay potency test for use with Generx, the company’s advanced clinical stage product candidate. For use by … Continue reading →

In a July interview conducted by CEOCFO Magazine, Cardium Therapeutics’ co-founder, Executive Chairman, and CEO, Christopher J. Reinhard, had an opportunity to explain the many developments that have occurred with the company since its founding in 2006, as well as … Continue reading →

Today before the opening bell, Cardium Therapeutics issued a press release detailing its financial results for the second quarter ended June 30, 2012, as well as reported on other recent developments including: (1) agreement with Advanced Biosciences Research, an affiliate … Continue reading →

My husband has type 2 diabetes, and since his diagnosis a year-and-a-half ago I’ve had to incorporate the word “carbohydrate” into my vocabulary and use it. Often. Diabetes is a real balancing act. If my husband eats too many carbs … Continue reading →

Cardium Therapeutics offers a dramatic new approach in the treatment of heart disease with the company’s product candidate Generx® (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic growth factor being developed for the treatment of patients with advanced coronary artery disease (CAD). … Continue reading →

Cardium Therapeutics just reported that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product has been named one of the top ten podiatry innovations this year by the publication Podiatry Today. The company also told investors that it will … Continue reading →

It wasn’t long ago that gene therapy, an idea that has been around since at least the early 1970s, was being derided as more hype than hope. Gene therapy basically involves identifying that part of a patient’s genetic makeup that … Continue reading →